DK3093018T3 - Farmaceutisk præparat indeholdende pyridylaminoeddikesyreforbindelse - Google Patents
Farmaceutisk præparat indeholdende pyridylaminoeddikesyreforbindelse Download PDFInfo
- Publication number
- DK3093018T3 DK3093018T3 DK15735133.9T DK15735133T DK3093018T3 DK 3093018 T3 DK3093018 T3 DK 3093018T3 DK 15735133 T DK15735133 T DK 15735133T DK 3093018 T3 DK3093018 T3 DK 3093018T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyridin
- pharmaceutical composition
- salt
- acetate
- glaucoma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (17)
1. Farmaceutisk præparat til behandling eller forebyggelse af glaukom eller okulær hypertension, omfattende 0,001 til 0,01 % (w/v) af isopropyl (6-{[4-(py-razol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetat eller et salt deraf.
2. Farmaceutisk præparat ifølge krav 1, omfattende 0,001 til 0,003 % (w/v) af isopropyl (6-{[4-(pyrazol-1 -yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyri-din-2-ylamino)acetat eller et salt deraf.
3. Farmaceutisk præparat ifølge krav 1, omfattende 0,0011 til 0,0030 % (w/v) af isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyri-din-2-ylamino)acetat eller et salt deraf.
4. Farmaceutisk præparat ifølge krav 1, omfattende 0,0011 til 0,0029 % (w/v) af isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyri-din-2-ylamino)acetat eller et salt deraf.
5. Farmaceutisk præparat ifølge krav 1, omfattende 0,0013 til 0,0027 % (w/v) af isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyri-din-2-ylamino)acetat eller et salt deraf.
6. Farmaceutisk præparat ifølge krav 1, omfattende 0,0015 til 0,0025 % (w/v) af isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyri-din-2-ylamino)acetat eller et salt deraf.
7. Farmaceutisk præparat ifølge krav 1, omfattende 0,0010 % (w/v), 0,0011 % (w/v), 0,0012 % (w/v), 0,0013 % (w/v), 0,0014 % (w/v), 0,0015 % (w/v), 0,0016 % (w/v), 0,0017% (w/v), 0,0018 % (w/v), 0,0019 % (w/v), 0,0020 % (w/v), 0,0021 % (w/v), 0,0022 % (w/v), 0,0023 % (w/v), 0,0024 % (w/v), 0,0025 % (w/v), 0,0026 % (w/v), 0,0027 % (w/v), 0,0028 % (w/v), 0,0029 % (w/v) eller 0,0030 % (w/v) af isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsul-fonyl)aminomethyl}pyridin-2-ylamino)acetat eller et salt deraf.
8. Farmaceutisk præparat ifølge krav 1, omfattende 0,0011 % (w/v), 0,0012 % (w/v), 0,0013 % (w/v), 0,0014 % (w/v), 0,0015 % (w/v), 0,0016 % (w/v), 0,0017 % (w/v), 0,0018 % (w/v), 0,0019 % (w/v), 0,0020 % (w/v), 0,0021 % (w/v), 0,0022 % (w/v), 0,0023 % (w/v), 0,0024 % (w/v), 0,0025 % (w/v), 0,0026 % (w/v), 0,0027 % (w/v), 0,0028 % (w/v), 0,0029 % (w/v) eller 0,0030 % (w/v) af isopropyl (6-{[4-(pyrazol-1 -yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyri-din-2-ylamino)acetat eller et salt deraf.
9. Farmaceutisk præparat ifølge krav 1, omfattende 0,0011 % (w/v), 0,0012 % (w/v), 0,0013 % (w/v), 0,0014 % (w/v), 0,0015 % (w/v), 0,0016 % (w/v), 0,0017 % (w/v), 0,0018 % (w/v), 0,0019 % (w/v), 0,0020 % (w/v), 0,0021% (w/v), 0,0022 % (w/v), 0,0023 % (w/v), 0,0024 % (w/v), 0,0025 % (w/v), 0,0026 % (w/v), 0,0027 % (w/v), 0,0028 % (w/v) eller 0,0029 % (w/v) af isopropyl (6-{[4-(pyrazol-l-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)ace-tat eller et salt deraf.
10. Farmaceutisk præparat ifølge krav 1, omfattende 0,002 % (w/v) af isopro-Pyl(6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-yla-mino)acetat eller et salt deraf.
11. Farmaceutisk præparat ifølge et af kravene 1 til 10, hvor en doseringsform er en øjendråbe.
12. Farmaceutisk præparat ifølge et af kravene 1 til 11, som anvendes til at blive inddryppet i øjet en gang eller to gange om dagen.
13. Farmaceutisk præparat ifølge et af kravene 1 til 12, som anvendes til at blive inddryppet i øjet i en dosis af en eller to dråber.
14. Farmaceutisk præparat ifølge et af kravene 1 til 13, som anvendes til at blive inddryppet i øjet en gang om dagen i en dosis afen dråbe.
15. Farmaceutisk præparat ifølge et af kravene 1 til 11 til anvendelse i en fremgangsmåde til behandling eller forebyggelse af glaukom eller okulær hypertension, hvor det farmaceutiske præparat inddryppes i øjet en gang eller to gange om dagen.
16. Farmaceutisk præparat ifølge et af kravene 1 til 11 til anvendelse i en fremgangsmåde til behandling eller forebyggelse af glaukom eller okulær hypertension, hvor det farmaceutiske præparat inddryppes i øjet i en dosis af en eller to dråber.
17. Farmaceutisk præparat ifølge et af kravene 1 til 11 til anvendelse i en fremgangsmåde til behandling eller forebyggelse af glaukom eller okulær hypertension, hvor det farmaceutiske præparat inddryppes i øjet en gang om dagen i en dosis af en dråbe.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925882P | 2014-01-10 | 2014-01-10 | |
| PCT/JP2015/050366 WO2015105144A1 (ja) | 2014-01-10 | 2015-01-08 | ピリジルアミノ酢酸化合物を含む医薬製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3093018T3 true DK3093018T3 (da) | 2019-02-04 |
Family
ID=53520400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15735133.9T DK3093018T3 (da) | 2014-01-10 | 2015-01-08 | Farmaceutisk præparat indeholdende pyridylaminoeddikesyreforbindelse |
Country Status (26)
| Country | Link |
|---|---|
| US (9) | US9415038B2 (da) |
| EP (3) | EP3750541A1 (da) |
| JP (7) | JP5846338B2 (da) |
| KR (1) | KR101824829B1 (da) |
| CN (2) | CN108743587B (da) |
| AU (1) | AU2015205188B2 (da) |
| BR (1) | BR112016015763B8 (da) |
| CA (1) | CA2936026C (da) |
| CL (1) | CL2016001756A1 (da) |
| DK (1) | DK3093018T3 (da) |
| EA (1) | EA031734B1 (da) |
| ES (2) | ES2834334T3 (da) |
| GE (1) | GEP20186917B (da) |
| HK (1) | HK1223036A1 (da) |
| HU (1) | HUE041653T2 (da) |
| IL (1) | IL246447B (da) |
| MX (1) | MX370361B (da) |
| MY (1) | MY163235A (da) |
| PH (1) | PH12016501357B1 (da) |
| PL (1) | PL3093018T3 (da) |
| PT (1) | PT3093018T (da) |
| SG (1) | SG11201605653RA (da) |
| TR (1) | TR201902019T4 (da) |
| TW (1) | TWI598113B (da) |
| UA (1) | UA117506C2 (da) |
| WO (1) | WO2015105144A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3750541A1 (en) | 2014-01-10 | 2020-12-16 | Santen Pharmaceutical Co., Ltd | Pharmaceutical preparation containing pyridylaminoacetic acid compound |
| TWI612960B (zh) * | 2014-01-10 | 2018-02-01 | Santen Pharmaceutical Co Ltd | 吡啶基胺基乙酸化合物及含聚氧乙烯蓖麻油之醫藥組成物 |
| WO2015105135A1 (ja) * | 2014-01-10 | 2015-07-16 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物含有医薬組成物 |
| KR20170093839A (ko) * | 2014-12-12 | 2017-08-16 | 코와 가부시키가이샤 | 수성 조성물 |
| TWI755356B (zh) * | 2015-07-01 | 2022-02-21 | 日商參天製藥股份有限公司 | 含檸檬酸酯之緩釋劑之用途 |
| ES2950461T3 (es) * | 2015-07-09 | 2023-10-10 | Santen Pharmaceutical Co Ltd | Agente preventivo y/o terapéutico que contiene un compuesto de ácido piridilaminoacético para el tratamiento de una enfermedad que involucra una presión intraocular muy elevada |
| US20200121652A1 (en) | 2017-06-16 | 2020-04-23 | The Doshisha | Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent |
| US11433090B2 (en) | 2017-06-16 | 2022-09-06 | The Doshisha | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
| US10940144B2 (en) | 2017-09-29 | 2021-03-09 | Santen Pharmaceutical Co., Ltd. | Drug containing pyridylaminoacetic acid compound |
| KR20200103041A (ko) | 2017-12-21 | 2020-09-01 | 산텐 세이야꾸 가부시키가이샤 | 오미데네팍의 조합 |
| CA3087019A1 (en) | 2017-12-28 | 2019-07-04 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical preparation containing pyridyl aminoacetic acid compound |
| JP6946575B2 (ja) * | 2018-04-24 | 2021-10-06 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 眼の状態の治療のためのピロカルピン塩酸塩の使用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002356420A (ja) * | 2001-03-27 | 2002-12-13 | Santen Pharmaceut Co Ltd | 安定な水性液剤 |
| DK2264009T3 (da) | 2008-03-12 | 2019-04-15 | Ube Industries | Pyridylaminoeddikesyreforbindelse |
| WO2010113957A1 (ja) * | 2009-03-30 | 2010-10-07 | 宇部興産株式会社 | 緑内障の治療又は予防のための医薬組成物 |
| JP2011057633A (ja) | 2009-09-11 | 2011-03-24 | Ube Industries Ltd | ピリジルアミノ酢酸化合物を含有する医薬 |
| US20120202863A1 (en) * | 2011-02-03 | 2012-08-09 | Gerald Horn | Compositions and methods for treatment of glaucoma |
| US9339496B2 (en) * | 2012-07-13 | 2016-05-17 | Santen Pharmaceutical Co., Ltd. | Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist |
| JP2014019650A (ja) * | 2012-07-13 | 2014-02-03 | Santen Pharmaceut Co Ltd | スルホンアミド化合物とタフルプロストの組み合わせ |
| US20140018350A1 (en) | 2012-07-13 | 2014-01-16 | Asahi Glass Co., Ltd. | Combination of sulfonamide compound and tafluprost |
| KR102074020B1 (ko) * | 2012-07-13 | 2020-02-05 | 산텐 세이야꾸 가부시키가이샤 | 술폰아미드 화합물의 조합 |
| EP3750541A1 (en) | 2014-01-10 | 2020-12-16 | Santen Pharmaceutical Co., Ltd | Pharmaceutical preparation containing pyridylaminoacetic acid compound |
| TWI612960B (zh) | 2014-01-10 | 2018-02-01 | Santen Pharmaceutical Co Ltd | 吡啶基胺基乙酸化合物及含聚氧乙烯蓖麻油之醫藥組成物 |
| WO2015105135A1 (ja) * | 2014-01-10 | 2015-07-16 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物含有医薬組成物 |
-
2015
- 2015-01-08 EP EP20183949.5A patent/EP3750541A1/en not_active Withdrawn
- 2015-01-08 HK HK16111395.0A patent/HK1223036A1/zh unknown
- 2015-01-08 CN CN201811020654.5A patent/CN108743587B/zh active Active
- 2015-01-08 EA EA201691402A patent/EA031734B1/ru unknown
- 2015-01-08 TR TR2019/02019T patent/TR201902019T4/tr unknown
- 2015-01-08 GE GEAP201514239A patent/GEP20186917B/en unknown
- 2015-01-08 DK DK15735133.9T patent/DK3093018T3/da active
- 2015-01-08 CA CA2936026A patent/CA2936026C/en active Active
- 2015-01-08 AU AU2015205188A patent/AU2015205188B2/en active Active
- 2015-01-08 PT PT15735133T patent/PT3093018T/pt unknown
- 2015-01-08 PL PL15735133T patent/PL3093018T3/pl unknown
- 2015-01-08 SG SG11201605653RA patent/SG11201605653RA/en unknown
- 2015-01-08 EP EP15735133.9A patent/EP3093018B1/en active Active
- 2015-01-08 ES ES18190494T patent/ES2834334T3/es active Active
- 2015-01-08 TW TW104100502A patent/TWI598113B/zh active
- 2015-01-08 UA UAA201607988A patent/UA117506C2/uk unknown
- 2015-01-08 ES ES15735133T patent/ES2711091T3/es active Active
- 2015-01-08 MY MYPI2016001271A patent/MY163235A/en unknown
- 2015-01-08 JP JP2015527691A patent/JP5846338B2/ja active Active
- 2015-01-08 MX MX2016009063A patent/MX370361B/es active IP Right Grant
- 2015-01-08 HU HUE15735133A patent/HUE041653T2/hu unknown
- 2015-01-08 CN CN201580003994.5A patent/CN105899209B/zh active Active
- 2015-01-08 BR BR112016015763A patent/BR112016015763B8/pt active IP Right Grant
- 2015-01-08 EP EP18190494.7A patent/EP3424503B1/en not_active Not-in-force
- 2015-01-08 KR KR1020167018735A patent/KR101824829B1/ko active Active
- 2015-01-08 WO PCT/JP2015/050366 patent/WO2015105144A1/ja not_active Ceased
- 2015-01-08 US US14/592,167 patent/US9415038B2/en active Active
- 2015-11-09 JP JP2015219845A patent/JP6491588B2/ja active Active
-
2016
- 2016-06-26 IL IL246447A patent/IL246447B/en active IP Right Grant
- 2016-07-08 PH PH12016501357A patent/PH12016501357B1/en unknown
- 2016-07-08 CL CL2016001756A patent/CL2016001756A1/es unknown
- 2016-07-18 US US15/212,592 patent/US9943510B2/en not_active Ceased
-
2018
- 2018-02-13 US US15/895,100 patent/US10179127B2/en active Active
- 2018-08-28 US US16/114,721 patent/USRE48183E1/en active Active
- 2018-12-06 US US16/211,839 patent/US10702511B2/en active Active
-
2019
- 2019-03-01 JP JP2019037654A patent/JP6785330B2/ja active Active
-
2020
- 2020-05-29 US US16/887,108 patent/US11197849B2/en active Active
- 2020-10-26 JP JP2020178844A patent/JP7087040B2/ja active Active
-
2021
- 2021-11-08 US US17/521,031 patent/US11793798B2/en active Active
-
2022
- 2022-06-08 JP JP2022092999A patent/JP7402922B2/ja active Active
-
2023
- 2023-09-11 US US18/464,646 patent/US12295946B2/en active Active
- 2023-12-11 JP JP2023208468A patent/JP7726542B2/ja active Active
-
2025
- 2025-04-08 US US19/173,125 patent/US20250235439A1/en active Pending
- 2025-07-31 JP JP2025128043A patent/JP2025142352A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12295946B2 (en) | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | |
| WO2017006985A1 (ja) | ピリジルアミノ酢酸化合物を含有する予防及び／又は治療剤 | |
| HK1225280A1 (en) | Pharmaceutical preparation including pyridylamino acetic acid compound | |
| HK1225280B (en) | Pharmaceutical preparation including pyridylamino acetic acid compound |